louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04020120: Assessment of the Professional Difficulties of Adult With Attention Deficit / Hyperactivity Disorder Patients
Official title: Impact of Adult With Attention Deficit / Hyperactivity Disorder on Professional Activity, a Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Attention Deficit Hyperactivity Disorder in Adults
Keywords: Prospective
Descriptive
Non-interventional
Monocentric
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2019-07-15
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 62
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who consulted at the psychiatric clinic of Strasbourg, aged 18 to 62, with a diagnosis of attention deficit disorder with or without hyperactivity assessed by a psychiatrist, and who have been in a working situation in the last 3 months.

Brief summary: Attention Deficit/Hyperactivity Disorder (ADHD), which is common and well known in children, persists into adulthood in more than 60% of cases, with significant impact on quality of life. Professional domain is particularly impaired.

The investigators hypothesize that ADHD symptoms causes professional difficulties, on the emotional, cognitive, physical and relational levels.

The main objective of this study is to better characterize these professional difficulties at to follow-up these difficulties after one year. Difficulties will be assessed by questionnaires and semi-directive interview.

The secondary objective is to determine what factors modulate these difficulties and what compensation strategies are implemented to address the patients.


Eligibility criteria: Inclusion criteria:

* Patients aged 18 to 62 years
* Diagnosis of attention deficit disorder with or without hyperactivity by a psychiatrist
* No treatment for ADHD in childhood or adolescence
* Patient who has been in a professional situation during the last 3 months

Exclusion criteria:

* Patient on sick leave or unemployed for more than 3 months
* Depressive episode in acute phase
* Subject with a mobility project that prevents follow-up for 1 year (planned move)
* Impossibility of providing the subject with informed information (subject in an emergency situation, difficulties in understanding the subject, mental retardation, illiteracy or insufficient command of the French language...)
* Subject under the protection of justice
* Subject under guardianship or curatorship

Primary outcomes:
measure: The Work Limitations Questionnaire (WLQ-25)
timeFrame: 1 year
Secondary outcomes:
measure: Maslach Burnout Inventory
timeFrame: 1 year
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Les Hôpitaux Universitaires de Strasbourg
Study officials:
References:
Clinical trial NCT02480920: Adherence to New Oral Anticoagulation Therapy in Turkey
Official title: Drug Adherence in Patients Taking New Oral Anticoagulation Therapy in Turkey
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation Drug Adherence
New Oral Anticoagulants
Drug Adherence
Lead sponsor: Cardiovascular Academy Society, Turkey
Sponsor class: OTHER
First posted: 2015-06-25
Enrollment: 2738
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Outpatients using a NOAC for at least 3 months duration, with a primary diagnosis of new-onset, non-valvular atrial fibrillation

Brief summary: This study will compose a national database of drug adherence and investigate the factors that affect drug adherence in patients taking new oral anticoagulation therapy in Turkish Population.

Detailed description: NOACs have several clinical and pharmacological advantages over warfarin however suboptimal adherence is one of the most common causes of failure to respond to medications and outcomes.

This observational multicenter, retrospective study, will compose a national database of drug adherence and investigate the factors that affect drug adherence in patients taking new oral anticoagulation therapy in Turkey.

Social support and adherence to therapy factors that may affect drug adherence and adverse events will be assessed by self-report questionnaires.

Non-adherence will be tested for demographic, clinical, awareness of NOAC therapy and socioeconomic factors.

Eligibility criteria: Inclusion Criteria:

* Patients \>18 years old
* Outpatients using a NOAC for at least 3 months duration, with a primary diagnosis of new-onset, non-valvular atrial fibrillation
* Patients signed patient informed sheet and informed consent form

Exclusion Criteria:

* Patients under 18 years old
* Patients refused to sign informed consent form

Primary outcomes:
measure: Compliance of NOACs in Turkish Population
timeFrame: 10 months
Secondary outcomes:
Other outcomes:
Locations:
city: Afyonkarahi̇sar
country: Turkey
facility: Volkan Emren
Study officials:
affiliation: Cardiovascular Academy Society, İzmir, Turkey
name: Volkan Emren, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05004220: Effects of Plasmapheresis on Aging Biomarkers
Official title: Studie Vlivu darování krevní Plazmy - Plasmapheresis. Study of the Plasma Donation Effect - Plasmapheresis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aging
Plasmapheresis
Keywords: Aging
Plasmapeheresis
Lead sponsor: Charles University, Czech Republic
Sponsor class: OTHER
Collaborators: name: University Hospital Hradec Kralove
name: Longevitytech.fund a.s.
name: Clock Foundation
name: AGECURVE LIMITED
First posted: 2021-08-13
Enrollment: 41
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 41 donors are welcomed to begin with the study. The participants are divided into 2 groups (Group 1 = therapeutic, Group 2 = half control) using stratified randomization, major criteria being chronological age and BMI, minor criteria being illness/medication, smoking, COVID in past 3 months, covid vaccination.

Group 1 consists of 28 participants (14 female, 14 male). Group 2 consists of 13 participants (7 female, 6 male). We suppose that the number of participants will decline during each phase of the study, approx. 10% before it even starts, 10% in the middle, 10% in the end. The goal is to have more than 30 participants finishing the study.

Brief summary: The aim of the study is to evaluate the effect of plasmapheresis (repeated plasma withdrawals) on selected health indicators (hematological, biochemical, immunological and indicators of biological age) of plasma donors.


Eligibility criteria: Inclusion Criteria:

1. Generally healthy volunteer subjects age 40 - 60
2. 50:50 man and woman

Exclusion Criteria:

1. Subjects excluded from plasma donation protocols (serious illness, infection, etc)
2. Subjects undergoing stronger anti-aging interventions

Primary outcomes:
measure: Significant change of biological age according to epigenetic clock after 8 plasmaphereses
timeFrame: Through study completion, an average of 8 months
Secondary outcomes:
measure: Significant change of biological age according to epigenetic clock after 8 plasmaphereses
timeFrame: Through study completion, an average of 8 months
measure: Significant change of the proteomic profile after 8 plasmaphereses
timeFrame: Through study completion, an average of 8 months
measure: Significant change of the proteomic profile after 4 plasmaphereses
timeFrame: Through study completion, an average of 8 months
measure: Significant change of the biological age according to a blood biochemistry clock after 8 plasmaphereses
timeFrame: Through study completion, an average of 8 months
measure: Significant change of the biological age according to a blood biochemistry clock after 4 plasmaphereses
timeFrame: Through study completion, an average of 8 months
Other outcomes:
Locations:
city: Hradec Králové
country: Czechia
facility: Charles University, Medical Faculty in Hradec Kralove
Study officials:
References:
Clinical trial NCT02570620: Contribution of Ultrasonography in the Evaluation of Cervical Induction-delivery Time
Official title: Apport de l'échographie du Col Dans l'évaluation du Délai Induction Accouchement (DIA) Chez Des Patientes à Score de Bishop défavorable après déclenchement Par Dinoprostone Intravaginal
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Delivery Uterine
Birth; Induced
Lead sponsor: University Hospital, Tours
Sponsor class: OTHER
First posted: 2015-10-07
Enrollment: 342
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Study of the contribution of ultrasound measurements of the uterine cervix related to the calculation of Bishop score. Evaluation of the period between cervical induction and delivery. Study of ultrasound data to improve the care of these patients requiring induction.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Single pregnancy to term (\> 37 weeks) in cephalic presentation
* Bishop score on the day of inclusion equal to 4.5 or 6
* Medical indication in accordance with professional recommendations of the April 2008 HAS.

Exclusion Criteria:

* Cicatricial uterus
* Placenta previa
* Parity \> 3 (more than 3 previous deliveries \> 22 weeks)
* History of cone biopsy and strapping
* Known fetal malformation
* Known allergy to prostaglandins
* Woman under guardianship

Primary outcomes:
measure: Time in hours between induction of prostaglandins and delivery
timeFrame: On the day of inclusion after induction of prostaglandins. In relation to the time of delivery.
Secondary outcomes:
Other outcomes:
Locations:
city: Nantes
country: France
facility: University Hospital of Nantes
city: Orleans
country: France
facility: Hospital of Orleans
city: Tours
country: France
facility: University Hospital of Tours
Study officials:
affiliation: University Hospital, Tours
name: Jérôme POTIN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00954473: Study of Blood Samples From Patients With Osteosarcoma
Official title: Retrospective Study of Genetic Risk Factors for Osteosarcoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Localized Osteosarcoma
Metastatic Osteosarcoma
Recurrent Osteosarcoma
Lead sponsor: Children's Oncology Group
Sponsor class: NETWORK
Collaborators: name: National Cancer Institute (NCI)
First posted: 2009-08-07
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All osteosarcoma patients seen at COG institutions are eligible

Brief summary: This research trial studies blood samples from patients with osteosarcoma. Studying the genes found in samples of blood from patients with osteosarcoma may help doctors identify biomarkers related to the disease.

Detailed description: PRIMARY OBJECTIVE:

I. Conduct a large-scale candidate gene association study in osteosarcoma (OS) using cases from the national Children's Oncology Group (COG) OS biology study (P9851 and successor study AOST06B1).

SECONDARY OBJECTIVES:

I. Conduct a genome-wide association study (GWAS) of OS. II. Fine-map genomic regions associated with OS to identify putative functional loci.

III. Conduct whole-exome sequencing of germline OS deoxyribonucleic acid (DNA) samples.

IV. Investigate the functional implications of promising genetic variants associated with OS.

OUTLINE:

Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and haplotypes to examine genetic variation, gene-gene interactions, and the population structure.

Eligibility criteria: Inclusion Criteria:

* Blood samples collected from clinical trials COG-P9851 and COG-AOST06B1

Primary outcomes:
measure: Hardy-Weinberg equilibrium on all SNPs
timeFrame: Baseline
measure: SNPs associated with OS
timeFrame: Baseline
measure: Gene-gene interactions
timeFrame: Baseline
measure: Survival outcomes
timeFrame: Baseline
measure: Whole-exome variant loci
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Arcadia
country: United States
facility: Children's Oncology Group
state: California
Study officials:
affiliation: Children's Oncology Group
name: Sharon Savage, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02738073: Effects of Tranexamic Acid on Blood Loss and Transfusion Requirement Following Hip Fracture
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hip Fracture
Lead sponsor: Rothman Institute Orthopaedics
Sponsor class: OTHER
First posted: 2016-04-14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: Tranexamic acid (TA) inhibits fibrinolysis by binding to lysine binding-sites of plasminogen to fibrin. Fibrinolysis is stimulated by surgical trauma, and the administration of TA has been shown effective in decreasing blood loss both intra-operatively and in the immediate post-operative period in elective hip and knee arthroplasty patients. Both the timing and dosing of TA has been investigated in these patients. Subsequent blood transfusion rate has also been shown to decrease as result of TA administration. Despite the support for TA utilization that exists in the arthroplasty literature, the data is scarce regarding its administration during surgical treatment of hip fractures. This is patient population who is at high risk for transfusion due to symptomatic post-operative anemia. This study aims to investigate whether TA's advantageous effects in the arthroplasty patient population can be extrapolated to the more unstable, heterogeneous hip fracture patient population. If the study is able to show a difference in blood loss and transfusion requirement, the long term implications of this with regards to cost and mortality can be significant.


Eligibility criteria: Inclusion Criteria:

Patients admitted to Bryn Mawr Hospital with fracture of the femoral neck, intertrochanteric region, or subtrochanteric region of the femur will be considered for the study.

Exclusion Criteria:

Exclusion criteria include

* age under 18
* allergy to TA
* known current or history of venous thromboembolism (VTE)
* history of known coagulopathy or bleeding disorder
* current subarachnoid hemorrhage
* previous history of seizures
* current use of estrogen/progesterone therapy
* renal failure defined as creatinine clearance less than 30 ml/min4
* multiple fractures
* pregnant or breastfeeding women
* planned nonoperative management of the fracture

Primary outcomes:
measure: calculation of blood loss during the perioperative period
timeFrame: participants will be followed for the duration of hospital stay, an expected average of 2-3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Bryn Mawr
country: United States
facility: Bryn Mawr Hospital
state: Pennsylvania
Study officials:
References:
Clinical trial NCT02944773: Assessment of Facilitated Tucking During the Procedure of Daily Weight on the Level of Stress in Preterm Infants
Official title: Assessment of Facilitated Tucking During the Procedure of Daily Weight on the Level of Stress in Preterm Infants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stress
Keywords: newborn
facilitated tucking
position
weight
stress
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
Collaborators: name: Spanish Clinical Research Network - SCReN
First posted: 2016-10-26
Enrollment: 20
Sex: ALL
Minimum age (years): 5
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: Randomized crossover clinical trial in which is intended to assess the effect of facilitated tucking of premature infants during daily weight. Heart rate, respiratory rate and neo-scale stress (ALPS-Neo) be observed before, during and one hour after the weight, and compared with normal practice, without facilitated tucking device.

Detailed description: Population(n): 20 newborn When a patient is a possible candidate, consent will be asked their parents. After obtaining informed consent signed by parents, it will be assigned a random group (G1, G2). In the G1, the first weight without facilitated tucking device and the next day with facilitated tucking device will be held. G2 will be done in reverse.

Handling pre phase (T0): at least 20 minutes before vitals heart rate and respiratory rate are taken in five times.

handling phase (T1): 1. the facilitated tucking device is placed. 2. will wait five minutes and weight will be held in the incubator;at the time of leaving it in the incubator the same constants are taken.

post handling phase (T2): the same constants are taken one hour after such manipulation.

Eligibility criteria: Inclusion Criteria:

* ≤1500 grams newborns
* a week of life about

Exclusion Criteria:

* Surgery
* Hemodynamic instability requiring vasoactive drugs
* Sedation
* Phototherapy at the time of the procedure
* Congenital anomalies.

Primary outcomes:
measure: Heart rate and breathing rate will be decreased compared to baseline measurement.
timeFrame: one year
Secondary outcomes:
measure: Behavioral signs
timeFrame: one year
Other outcomes:
Locations:
city: Castelldefels
country: Spain
facility: Silvia Vicente Pérez
state: Barcelona
Study officials:
affiliation: Fundació de Gestió Sanitària de l'Hospital de la Santa Creu i Sant Pau
name: silvia Vicente Pérez
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06717373: Point-of-Care Echocardiography in Patients with Known or Suspected Aortic Stenosis
Official title: Point-of-Care Echocardiography in Patients with Known or Suspected Aortic Stenosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Patients with an Indication for an Echocardiographic Examination with Suspicion of Valcular Heart Disease
Lead sponsor: Caption Health, Inc.
Sponsor class: INDUSTRY
First posted: 2024-12-05
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This is a prospective, non-randomized, un-blinded study in patients scheduled for a standard echocardiographic examination.
Primary purpose: DIAGNOSTIC

Brief summary: This is a prospective clinical trial intended to capture echocardiographic images in patients clinically indicated for an echocardiographic examination using an additional Point of Care Ultrasound device . The images collected will be used to test and possibly validation an AI base Aortic Valve Stenosis algorithm

Detailed description: This is a non-randomized, un-blinded single-arm study in patients scheduled for a standard echocardiographic examination. Participants will be scanned by a sonographer (Study Exam) and 6 standard views will be obtained using both the ultrasound systems: PLAX, PSAX-AV, AP4, AP2, AP3 and AP5 .

The patient will undergo their scheduled echocardiographic examination either before or after the study examinations.

The findings from the clinically indicated echocardiographic examination will be used as a gold standard for the presence/absence and severity of aortic stenosis.

The first 45 patients, 15 with mild, 15 with moderate and 15 with severe AS, will be used for testing and possible fine-tuning the AutoAS algorithm for each Study Device, and the remaining up to 155 patients for each Study Device will be used for clinical validation of the algorithm. Because these first 45 patients will only be used for possible fine-tuning the AutoAS algorithm, they will be excluded from endpoint analysis.

Eligibility criteria: Inclusion Criteria:

* Patients scheduled for an echocardiographic examination
* Patients ≥18 years old
* Patient with known or suspected valve disease based on medical history

Exclusion Criteria:

* Patients with artificial aortic valves
* Unable to lie flat for study
* Patients experiencing a known or suspected acute cardiac event
* Patients unwilling or unable to give written informed consent

Primary outcomes:
measure: Sensitivity and Specificity
timeFrame: At the time of the examination
Secondary outcomes:
measure: Subgroup analysis of outcome 1
timeFrame: At the time of the examination
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
Study officials:
affiliation: Northwestern University
name: Akhil Narang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00997373: Letrozole as a Treatment of Endometrial Cancer
Official title: Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endometrial Carcinoma
Keywords: Endometrial Cancer
Endometrial Carcinoma
Aromatase Inhibitor
Letrozole
Femara
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2009-10-19
Enrollment: 43
Sex: FEMALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.


Eligibility criteria: Inclusion Criteria:

* FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium
* Post menopausal status must be demonstrated
* Signed informed consent

Exclusion Criteria:

* FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the endometrium
* Younger than 40 or postmenopausal status not established
* Pregnant or breastfeeding

Primary outcomes:
measure: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer
timeFrame: At time of consent and after hysterectomy (generally about 3 weeks)
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis
state: California
city: Sacramento
country: United States
facility: University of California, Davis
state: California
Study officials:
affiliation: University of California, Davis
name: Lloyd H. Smith, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: